Adverse drug events complicate antifungal therapy for pulmonary aspergilloma

Consultant Pharmacist

Volumn 23, Issue 10, 2008, Pages 804-808

  Pakyz, Amy ^a   Bearman, Gonzalo ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTIFUNGAL AGENT; ITRACONAZOLE; POSACONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

AGED; AGITATION; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPERGILLUS; CASE REPORT; CONGESTIVE HEART FAILURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; HALLUCINATION; HUMAN; IMMUNOCOMPROMISED PATIENT; LOBECTOMY; LUNG ASPERGILLOSIS; LUNG CANCER; MALE; NONHUMAN; SIDE EFFECT;

EID: 54249155567     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2008.804     Document Type: Article

References (14)

1. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-60.
2. Judson MA, Stevens DA. The treatment of pulmonary aspergilloma. Curr Opin Invest Drugs 2001;2:1375-7.
3. Boucher HW, Groll AH, Chiou CC et al. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004;64:1997-2020.
4. Voriconazole (VFEND) package insert. New York, NY: Pfizer; rev March 2008.
5. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36:630-7.
6. Agrawal AK, Sherman LK. Voriconazole-induced musical hallucinations. Infection 2004;32:293-5.
7. Boyd AE, Modi S, Howard SJ et al. Adverse reactions to voriconazole. Clin Infect Dis 2004;39:1241-4.
8. Imhof A, Schaer DF, Schwarz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 2006;136:739-42.
9. Eiden C, Peyiere H, Cociglio M et al. Adverse effects of voriconazole: analysis of the French pharmacovigilance database. Ann Pharmacother 2007;41:755-63.
10. Itraconazole (Sporanox) package insert. Titusville, NJ: Janssen Pharmaceutica Products LP; rev 2001.
11. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet 2001;357:1766-7.
12. Tores HA, Hachem RY, Chemaly RF et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005;5:775-85.
13. Posaconazole (Noxafil) package insert. Kcnilworth, NJ: Schering Corporation; 2006.
14. Dubé MP, Stein JH, Aberg JA et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trial Group. Clin Infect Dis 2003;37:613-27.